cap 1

CAP-1 is an inhibitor of HIV-1 capsid formation.

CAP1-6D is a cytotoxic T lymphocyte (CTL) agonist peptide that enhances the immunogenicity of CAPI peptides and stimulates T cell responses.

1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) is a biotinylated phospholipid. It has been used in PEGylated polyamidoamine-dendrimer-conjugated supported lipid bilayers (SLB) to isolate circulating tumor cells and tumor cell microembolis from patient-derived blood by antibody-coated microfluidics. [1] It has also been used as a component of SLBs to detect protein-ligand binding with ortho-conjugated Texas Red DHPE. [2] In addition, 1,2-dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) has been used in SLBs partitioned into nanowells to create DNA curtains, which can be used as a high-throughput tool for detection of protein-DNA interactions at the single molecule level.[3]

PACAP 1-38 acetate is a pituitary adenylate cyclase activating polypeptide (PACAP) analogue. PACAP 1-38 acetate binds to PACAP type I receptor(IC50 = 4 nM) and PACAP type II VIP2 receptor(IC50 = 1 nM) but not to PACAP type II, VIP1 receptor.

CAP18 (rabbit) is a 37-amino-acid antimicrobial peptide derived from rabbit granulocytes, exhibiting extensive antimicrobial activity against both Gram-positive [IC50, 130-200 nM] and Gram-negative bacteria [IC50, 20-100 nM]. CAP18 (rabbit) holds promise for the study and advancement of bacterial sepsis research.

LL-37 (18-37), an antimicrobial peptide fragment of LL-37, exhibits activity against S. aureus and C. albicans, with minimum lethal concentrations of 4 µM and 10 µM, respectively. Additionally, it inhibits E. histolytica trophozoites growth at concentrations between 10 to 50 µM.

CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).

PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA), an N-terminal fragment of PACAP-38, is an effective PACAP receptor antagonist with IC50 values of 3 nM for rat PAC1, 2 nM for rat VPAC1, and 5 nM for human VPAC2.

PACAP (1-27) (the N-terminal fragment of PACAP-38) is a novel neuropeptides originally isolated from bovine hypothalamus, also found in humans and rats.

PACAP (1-27), human, ovine, rat acetate (PACAP 1-27 acetate) is a novel neuropeptides originally isolated from bovine hypothalamus, also found in humans and rats.

PACAP (1-38), human, ovine, rat (Pituitary Adenylate Cyclase Activating Polypeptide 38), is a neuropeptide comprising 38 amino acid residues.

NLRP3-IN-51 (Compound 3q) is an effective activator of the cholinergic anti-inflammatory pathway (CAP). This compound demonstrates potential for treating gouty arthritis as it inhibits the production of IL-1β in THP-1 cells induced by monosodium urate (MSU). Furthermore, NLRP3-IN-51 suppresses the phosphorylation of NF-κBp65 triggered by MSU without impacting the self-cleavage and activation of NLRP3, pro-caspase 1, or the second messenger caspase-1. Therefore, the initial stage of NLRP3 inhibition by NLRP3-IN-51 occurs through the activation of CAP.

Suberoylanilide hydroxamic acid (SAHA) is a class I and class II histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. [1] coumarin-Suberoylanilide hydroxamic acid (c-SAHA) is a SAHA derivative where the anilino cap" group is replaced by 7-amino-4-methylcoumarin to produce a fluorescent probe that competitively binds HDAC. [2] The fluorescence excitation and emission maxima of free c-SAHA is 325 and 400 nm

Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor, exhibiting inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC50s of 27.16 μM and 33.41 μM, respectively, and possessing anti-oxidant activity[1][2].

2',3'-O-Isopropylideneguanosine is an alkylated guanosine building block.1,2It has been used in the synthesis of ordered honeycomb microporous films and mRNA cap analogs. 1.Gao, Y.-F., Huang, Y.-J., Xu, S.-Y., et al.Ordered honeycomb microporous films from self-assembly of alkylated guanosine derivativesLangmuir27(6)2958-2964(2011) 2.Kore, A.R., Shanmugasundaram, M., and Vlassov, A.V.Synthesis and application of a new 2',3'-isopropylidene guanosine substituted cap analogBioorg. Med. Chem. Lett.18(17)4828-4832(2008)

7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, is utilized in the synthesis of mRNA cap analogues[1].

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

Cefditoren Pivoxil is an orally active antibiotic with broad-spectrum antibacterial properties, and Cefditoren demonstrates potent inhibition against both Gram-negative and Gram-positive bacterial pathogens. Cefditoren exhibits a MIC50 of 0.25–0.5 mg/L against Streptococcus pneumoniae, Cefditoren is widely used for treating respiratory tract infections and skin infections. Cefditoren remains valuable in antimicrobial therapy owing to its favorable pharmacokinetic characteristics and reliable therapeutic efficacy.

N7-Methylguanosine-5'-triphosphate-5'-adenosine (m7GpppA) diammonium, a dinucleotide cap analog, facilitates in vitro RNA transcription [1].

M7GpppApG is a trinucleotide mRNA 5' cap analog utilized for in vitro RNA synthesis [1].

3'Ome-m7GpppAmpG, a trinucleotide cap analogue with a locked nucleic acid (LNA) molecule, demonstrates notable translational efficiency. It serves as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes, including protein production, gene therapy, and anti-cancer immunization [1].

3'Ome-m7GpppAmpG ammonium, a trinucleotide Cap analogue with a locked nucleic acid (LNA) component, demonstrates substantial translational efficiency. It emerges as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes including protein production, gene therapy, and anti-cancer immunization [1].

M7GpppAmpG is a trinucleotide 5′ cap analog, exhibiting capping efficiencies of 90% for the produced RNAs [1].